Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)

Completed

• Conditions: Coronavirus Infection

• Registration Number: NCT04402905
• Lead Sponsor: Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

Brief Summary

COVID-19 is an infection linked to a new coronavirus: SARS-CoV-2, which appeared in Wuhan in China at the end of 2019, and which has since spread around the world, responsible for a new major pandemic, which is upsetting the whole world.

If severe respiratory disease is the form that constitutes the extreme gravity of the disease (mortality, with more than 170,000 deaths worldwide to date).

However, there is a great heterogeneity of clinical forms with asymptomatic or symptomatic pauci forms, moderate forms, up to severe forms.

Different symptoms may appear: fever, cough, asthenia, dyspnea, gastrointestinal forms, anosmia and / or ageusia, skin involvement, etc.

Given the novelty of this infection, several questions remain:

* What are all the symptoms that can be contracted by a COVID-19 patient?

* Are there clinical forms not described?

* What is the evolutionary profile, the healing time of this disease in patients treated on an outpatient basis?

* What are the factors associated with a prolonged form of COVID-19 disease, including on an outpatient basis?

Detailed Description

Most of the descriptive studies relating to COVID-19 relate to the severe forms of the disease managed in the hospital sector.

Few data have been published on moderate forms, requiring no hospitalization, of strict outpatient management.

These so-called moderate forms, however, constitute the majority of cases of COVID-19 (approximately 80%).

In the Infectious and Tropical Diseases Department of Pitie Salpetriere, COVIDOM pilot site, at the beginning of March, during the intensification of the epidemic in France, a weekly telephone consultation was set up to take care of people tested for COVID + by PCR, or people not tested by PCR, or even tested with negative PCR but symptomatic and followed at home, suffering from moderate form of COVID-19, as well as their contact cases if they wished.

Telemedicine is particularly suitable in this epidemic context, ensuring continuity of care, while limiting face-to-face consultations, thus reducing the risk of cross-contamination.

Given the novelty of this infection, it is important to be able to best characterize these ambulatory forms, as well as their evolution, in order to manage these patients, and to offer primary care physicians a more detailed description of these forms. , which they are and will be called upon to take care of, general medicine being central to dealing with the epidemic.

Study Timeline

• Study First Submitted: 2020-05-20
• Study First Submitted QC: 2020-05-25
• Study First Posted: 2020-05-27
• Study Start: 2020-06-15
• Primary Completion: 2020-07-15
• Study Completion: 2020-08-15
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-02
• Last Update Posted: 2021-02-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

• Age >18 years
• COVID PCR + patient: Patient screened positive by PCR on nasopharyngeal swab
• or COVID-like patient: Patient not screened, but considered COVID + because contact with a COVID PCR + person, and presenting symptoms suggestive of COVID-19 among:
• Influenza-like illness (fever, body aches, arthralgia, etc.)
• Respiratory form: dyspnea, cough, rhinitis
• Gastrointestinal form: diarrhea, nausea, vomiting
• Anosmia and / or ageusia
• or patient COVID PCR-: If patient tested negative by PCR on nasopharyngeal swab, but showing signs suggestive of COVID-19.

Exclusion Criteria

• Patient objecting to the use of their data for research purposes
• Patient under justice or deprived of liberty.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
COVID-PSL Cohort	3 months	measure of the absence of symptoms to assess the rate of complete clinical recovery on day 30

Trial Locations

Locations (1)

Yasmine Dudoit; 🇫🇷 Paris, France